Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Tectonic Therapeutic, Inc. is holding its 2026 Annual Meeting as a virtual-only audio webcast on June 8, 2026 at 9:00 a.m. Eastern Time for stockholders of record as of April 13, 2026. Holders of 18,848,500 shares of common stock may vote online, by phone, by mail, or during the meeting.
Stockholders will vote on electing two Class II directors, ratifying Deloitte & Touche LLP as independent auditor for 2026, and an advisory “say-on-pay” vote on executive compensation. The proxy details board structure, independence, committee responsibilities, and executive pay, including salary, cash bonuses, equity awards, and change-in-control severance protections.
Tectonic Therapeutic, Inc. appointed Jessica Chutter to its Board of Directors and Audit Committee, effective as of the company’s 2026 annual stockholder meeting, described in the press release as June 8, 2026. She will serve as a Class III director with a term expiring at the 2027 annual meeting and has been determined to be an independent director under Nasdaq rules.
As a non-employee director, Ms. Chutter is eligible for an annual cash retainer of $40,000 for Board service and $7,500 for Audit Committee service, plus a one-time option grant for 20,400 shares under the 2024 Equity Incentive Plan. The initial option vests over three years, and future annual option grants are expected after each stockholder meeting, with vesting tied to continued Board service and accelerated vesting upon a qualifying change in control.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy executed an open-market sale of 1,000 shares of Common Stock at $31.05 per share on April 1, 2026. She held 68,747 shares afterward, and the sale was made under a pre-established Rule 10b5-1 trading plan.
Tectonic Therapeutic, Inc. director Nader Francois received a grant of stock options covering 20,400 shares of common stock. The options have an exercise price of $30.78 per share and expire on March 31, 2036.
One third of the option vests on April 1, 2027, with the remaining two thirds vesting in 24 equal monthly installments, as long as Francois continues to provide service through each vesting date. Following this grant, the filing shows 20,400 derivative securities held directly.
Tectonic Therapeutic, Inc. director Nader Francois filed an initial Form 3, which reports his status as an insider of the company. The filing lists no buy, sell, or other reportable transactions and shows no derivative holdings at this time.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy reported an open-market sale of 10,000 shares of common stock on March 6, 2026 at a price of $30.00 per share. After this transaction, she directly holds 69,747 shares of the company’s common stock.
The sale was executed under a Rule 10b5-1 trading plan that she adopted on April 8, 2025, indicating the trades were pre-arranged under that plan rather than timed at her discretion.
Tectonic Therapeutic, Inc. Chief Scientific Officer Peter McNamara reported option exercises and share sales on March 6, 2026. He exercised employee stock options for 2,500 and 215 shares, which converted into common stock at exercise prices of $2.3800 and $14.7100 per share.
On the same date, he sold 6,047 shares of common stock at $30.0000 per share and 215 shares at $35.0000 per share in open‑market transactions. After these trades, he directly owned 55,285 shares of Tectonic Therapeutic common stock. The filing notes these exercises and sales were made under a Rule 10b5‑1 trading plan adopted on November 14, 2025.
PETER MCNAMARA reported insider sales of Common stock under 10b5-1 plans. The filing lists two 10b5-1 sale transactions: 1,650 shares on 03/04/2026 for $41,250.00 and 1,649 shares on 03/03/2026 for $36,376.94. The form also notes prior option exercises (3,547 and 2,715 shares with exercise dates shown).